STOCKHOLM, Sept. 30, 2019 /PRNewswire/ -- Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a result of exercise of warrants under the company's incentive programs.
Through the exercise of warrants under the company's incentive programs, the number of outstanding shares and votes has increased by 1,355,087 from 53,856,921 to 55,212,008. The share capital has increased by approximately SEK 150,565 from SEK 5,984,102 to SEK 6,134,668.
This is information that Oncopeptides AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact persons set out above, at 14:00 CEST on 30 September 2019.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological cancers. The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma, including the Phase 2 pivotal trial HORIZON currently underway and a global confirmatory Phase 3 trial (OCEAN) continuing enrollment. Oncopeptides' headquarters is located in Stockholm, Sweden, and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
For more information please visit www.oncopeptides.com.
For further information, please contact:Jakob Lindberg, CEO of OncopeptidesE-mail: email@example.com Telephone: +46-8-615-20-40
Rein Piir, Head of Investor Relations at OncopeptidesE-mail: firstname.lastname@example.org Cell phone: +46-70-853-72-92
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
|https://mb.cision.com/Main/15404/2920810/1115510.pdf||Press release - Number of Shares Oncopeptides|
SOURCE Oncopeptides AB